United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Endologix, Inc. to Announce First Quarter 2019 Financial Results on May 2, 2019
IRVINE, Calif. --(BUSINESS WIRE)--Apr. 15, 2019-- Endologix, Inc.  (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2019 after the market close on Thursday, May 2, 2019 .
View HTML
Toggle Summary Endologix Announces Equity Financing of $52 Million and Debt Restructuring Addressing 2020 Maturities and Financial Covenants
The Company reports preliminary revenue for the first quarter ending March 31, 2019 of at least $35 million The Company reiterates financial guidance for 2019 Transactions expected to close on or about April 3rd Endologix management to host conference call today at 8:30 a.m. ET IRVINE, Calif.
View HTML
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Mar. 20, 2019-- Endologix, Inc.  (Nasdaq:ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to nine newly hired employees (the “Awardees”).
View HTML
Toggle Summary Endologix Announces Approval of Reverse Stock Split
IRVINE, Calif. --(BUSINESS WIRE)--Mar. 5, 2019-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX) previously announced that a proposal was approved at its Special Meeting of Stockholders, held February 22, 2019 , authorizing its Board of Directors to amend the Company's certificate of incorporation
View HTML
Toggle Summary Endologix Reports Fourth Quarter and Fiscal Year 2018 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)--Feb. 25, 2019-- Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2018 .
View HTML
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Feb. 11, 2019-- Endologix, Inc.  (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to eight newly hired employees (the “Awardees”).
View HTML
Toggle Summary Endologix, Inc. to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on February 25, 2019
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 29, 2019-- Endologix, Inc.  (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the fourth quarter and fiscal year 2018 after the market close on Monday, February 25,
View HTML
Toggle Summary Endologix Provides Update on Previously Announced Voluntary Nellix System Recall
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 22, 2019-- Endologix® Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the EC Certificate of Conformity (CE Mark) for the Nellix EndoVascular Aneurysm Sealing System (Nellix System) has been
View HTML
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 11, 2019-- Endologix, Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to a newly hired executive (the “Awardee”).
View HTML
Toggle Summary Endologix Appoints John D. Zehren as Chief Commercial Officer
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 10, 2019-- Endologix, Inc. (Nasdaq:ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John D. Zehren as the Company’s Chief Commercial Officer, effective as of
View HTML
Toggle Summary Endologix Announces Fourth Quarter and Full-Year 2018 Preliminary Financial Results and Provides 2019 Financial Guidance
IRVINE, Calif. --(BUSINESS WIRE)--Jan. 7, 2019-- Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth quarter ended December 31, 2018 is expected to be
View HTML
Toggle Summary Endologix Takes Decisive Action to Optimize Patient Outcomes by Ensuring Nellix System Used Only within Current Indications
Voluntary Recall of Existing Inventory, New Cases Conducted Under Clinical Protocol, and Patient Selection Pre-Approved by Physician Panel Decision Aligns with European Society for Vascular Surgery Practice Guidelines No Change to Previously Issued Revenue Guidance for 2019 No Change to EVAS2 IDE
View HTML
Toggle Summary Endologix, Inc. to Present at the J.P. Morgan Healthcare Conference
IRVINE, Calif. --(BUSINESS WIRE)--Dec. 20, 2018-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko , Chief Executive Officer, and Vaseem Mahboob , Chief Financial Officer, will present at the 37 th Annual
View HTML
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Dec. 13, 2018-- Endologix, Inc.  (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to three newly hired employees (together, the “Awardees”).
View HTML
Toggle Summary Endologix Honors Innovators of Aortic Therapy at VEITHsymposium
IRVINE, Calif. --(BUSINESS WIRE)--Nov. 15, 2018-- Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today honored four innovators of aortic therapy at the 45 th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons
View HTML